TY - JOUR
T1 - Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors
AU - Chauhan, Aman
AU - Chan, Kelley
AU - Halfdanarson, Thorvardur R
AU - Bellizzi, Andrew M
AU - Rindi, Guido
AU - O'Toole, Dermot
AU - Ge, Phillip S
AU - Jain, Dhanpat
AU - Dasari, Arvind
AU - Anaya, Daniel A
AU - Bergsland, Emily
AU - Mittra, Erik
AU - Wei, Alice C
AU - Hope, Thomas A
AU - Kendi, Ayse T
AU - Thomas, Samantha M
AU - Flem, Sherlonda
AU - Brierley, James
AU - Asare, Elliot A
AU - Washington, Kay
AU - Shi, Chanjuan
PY - 2024
Y1 - 2024
N2 - The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP-NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP-NETs from poorly differentiated neuroendocrine carcinoma. In addition, because of major advancements in diagnostic and therapeutic technologies for GEP-NETs, AJCC version 9 advocates against the use of serum chromogranin A for the diagnosis and monitoring of GEP-NETs. Furthermore, AJCC version 9 recognizes the increasing role of endoscopy and endoscopic resection in the diagnosis and management of NETs, particularly in the stomach, duodenum, and colorectum. Finally, T1NXM0 has been added to stage I in these disease sites as well as in the appendix.
AB - The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP-NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP-NETs from poorly differentiated neuroendocrine carcinoma. In addition, because of major advancements in diagnostic and therapeutic technologies for GEP-NETs, AJCC version 9 advocates against the use of serum chromogranin A for the diagnosis and monitoring of GEP-NETs. Furthermore, AJCC version 9 recognizes the increasing role of endoscopy and endoscopic resection in the diagnosis and management of NETs, particularly in the stomach, duodenum, and colorectum. Finally, T1NXM0 has been added to stage I in these disease sites as well as in the appendix.
KW - American Joint Committee on Cancer (AJCC) version 9
KW - cancer staging protocols
KW - gastroenteropancreatic neuroendocrine tumors
KW - gastrointestinal neuroendocrine tumor
KW - pancreatic neuroendocrine tumor
KW - American Joint Committee on Cancer (AJCC) version 9
KW - cancer staging protocols
KW - gastroenteropancreatic neuroendocrine tumors
KW - gastrointestinal neuroendocrine tumor
KW - pancreatic neuroendocrine tumor
UR - https://publicatt.unicatt.it/handle/10807/301969
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85191883510&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85191883510&origin=inward
U2 - 10.3322/caac.21840
DO - 10.3322/caac.21840
M3 - Article
VL - 74
SP - 359
EP - 367
JO - Ca. A cancer journal for clinicians
JF - Ca. A cancer journal for clinicians
IS - 4
ER -
